Atlas Venture
 | |
| Company type | Private |
|---|---|
| Industry | Venture Capital |
| Founded | 1980 |
| Founder | Michiel de Haan[1] |
| Headquarters | Cambridge, Massachusetts, U.S. |
Key people | Kevin Bitterman Bruce Booth Jean-Francois Formela Michael Gladstone David Grayzel Jason Rhodes[2] |
| Products | venture capital funds |
| AUM | $2.2 billion |
Number of employees | 29 |
| Website | www.atlasventure.com |
Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located.[3] Atlas raised its thirteenth fund totaling $450 million in March 2022,[4] after raising its Opportunity Fund II totaling $300 million in September 2021.[5]
History
[edit]Originally formed in 1980 in Amsterdam as a subsidiary of NMB Bank, now part of ING Group, Atlas historically invested in both life sciences and information technology startup companies. In October 2014, Atlas announced its shift to a biotech-only venture capital firm, with the technology-focused investment team forming a new firm, Accomplice, to continue investing in information technology startups.[6][7] Previously as a diversified firm, Atlas had raised over $3.0 billion of investor commitments across nine venture capital funds. The firm raised $705 million for its 2000-vintage fifth fund, $600 million for its 2001-vintage sixth fund, $385 million for its 2006-vintage seventh fund, $283 million for its 2009-vintage eighth fund, and $265 million for its 2013-vintage ninth fund.[8][9] At its largest, the firm held European offices in London, Paris and Munich,[10] and a West Coast office based in Seattle, Washington, in addition to the Boston-area headquarters. Today, the firm operates from a single office in Cambridge, Massachusetts.[11][12]
In 2015 Atlas raised its first biotech-dedicated fund, Fund X, at $280 million. In 2017, Atlas Venture announced it had raised Fund XI at $350 million in capital to invest in early stage biotech companies in the U.S. and around the world.[13] In January 2019, Atlas Venture announced its Opportunity Fund I raised $250 million.[14] In June 2020, Atlas Venture announced its Fund XII raised $400 million.[15]
References
[edit]- ^ "Atlas History - Atlas Venture". Atlas Venture. Retrieved 2017-10-25.
- ^ "Atlas Team - Atlas Venture". Atlas Venture. Retrieved 2016-03-15.
- ^ Exclusive: Atlas Venture is splitting up. Fortune, October 2, 2014
- ^ Atlas Venture Announces $450 Million Fund XIII.
- ^ "Atlas Venture Announces $300 Million Second Opportunity Fund" (Press release). October 1, 2021.
- ^ "Atlas Venture: The Next Chapter - LifeSciVC". Life Sci VC. October 2, 2014.
- ^ Huang, Gregory T. (June 29, 2015). "FKA Atlas Has a New Name: Accomplice". Xconomy.
- ^ Atlas Venture Closes New Fund with $283M, Does the Staffing Shuffle. XConomy, January 2009
- ^ Atlas Venture aims for new $500M fund Archived 2012-10-04 at the Wayback Machine. Mass High Tech, November 6, 2008
- ^ Changes in the Atlas Venture partnership. Fortune, April 8, 2014
- ^ Atlas Venture ups sticks to Boston. Tech Crunch Europe, January 19, 2010
- ^ Atlas Brings Its European Ops Back to Boston. New York Times DealBook, January 20, 2010
- ^ "Atlas Venture Unveils New $350M Fund for Seed Biotech Investments | Xconomy". Xconomy. 2017-06-29. Retrieved 2017-07-26.
- ^ "As market shifts, Atlas Venture closes a $250 million fund to support its breakaway biotech bets". TechCrunch. 2 January 2019. Retrieved 2019-01-03.
- ^ de Crescenzo, Sara (June 5, 2020), Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs, Xconomy, retrieved March 17, 2021
